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Cyclic peptide FXII inhibitor provides safe
anticoagulation in a thrombosis model
and in artificial lungs
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Inhibiting thrombosis without generating bleeding risks is a major challenge in medicine. A
promising solution may be the inhibition of coagulation factor XII (FXII), because its knock-
out or inhibition in animals reduced thrombosis without causing abnormal bleeding. Herein,
we have engineered a macrocyclic peptide inhibitor of activated FXII (FXIIa) with sub-
nanomolar activity (Ki= 370 ± 40 pM) and a high stability (t1/2 > 5 days in plasma), allowing
for the preclinical evaluation of a first synthetic FXIIa inhibitor. This 1899 Da molecule, termed
FXII900, efficiently blocks FXIIa in mice, rabbits, and pigs. We found that it reduces ferric-
chloride-induced experimental thrombosis in mice and suppresses blood coagulation in an
extracorporeal membrane oxygenation (ECMO) setting in rabbits, all without increasing the
bleeding risk. This shows that FXIIa activity is controllable in vivo with a synthetic inhibitor,
and that the inhibitor FXII900 is a promising candidate for safe thromboprotection in acute
medical conditions.
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Coagulation stops the bleeding at sites of vessel wall injuries,but excess coagulation is equally dangerous as it can leadto thrombosis. Blood vessel blockages can occur in the
arterial and venous circulation and cause myocardial infarction,
ischemic stroke, and pulmonary embolism, which collectively are
the leading causes of disability and death in the industrialized
world1. In all of the anticoagulants widely used for the acute and
prophylactic treatment of thrombosis2,3, bleeding is a common
side effect, and the initiation of any therapy to treat thrombotic
disorders must always weigh these risks and benefits, considering
the severity of the potential side effects. Thus, there is a growing
need for the development of effective anticoagulants that ideally
would not impair hemostatic ability4.
A promising novel perspective for developing safe antic-
oagulants with reduced or no bleeding risks is the inhibition of
coagulation factors XII (FXII) and XI (FXI), both proteases of the
intrinsic coagulation pathway5,6. FXII is the initiating protease of
the procoagulant and proinflammatory contact system, and it
drives both the intrinsic pathway of coagulation and the
kallikrein-kinin system7. Mice lacking FXII display reduced
thrombosis in mouse models of injury-induced arterial and
venous thrombosis8,9 and are protected from pathological
thrombosis in cerebral ischemia10. At the same time, humans
naturally lacking FXII and FXII-knockout mice have a normal
hemostatic capacity and do not bleed abnormally8,11, which
supports the idea that drugs targeting the protease could poten-
tially display antithrombotic effects without significantly com-
promising hemostasis. Concordantly, the reduction of FXII
expression by antisense oligonucleotides suppresses thrombosis in
arterial and venous thrombosis mouse models and catheter
thrombosis in rabbits12,13. The inhibition of FXII by protein-
based inhibitors, such as antibodies14,15 or insect- and plant-
derived proteins16–18, also reduces thrombosis in mouse, rat,
rabbit, and primate models of induced arterial or venous
thrombosis and shows potential avenues for therapeutic
anticoagulation.
FXII-driven blood coagulation is a major challenge in cardio-
pulmonary bypass (CPB) surgeries in which a heart-lung machine
temporarily supports the circulation. Contact between FXII and
artificial surfaces, such as the oxygenator membrane or tubing,
induces a conformational change that leads to the proteolytic
activation of the FXII zymogen that turns on the contact system.
Activation of the procoagulant intrinsic coagulation pathway and
the proinflammatory kallikrein-kinin system leads to blood
clotting and inflammation19. Contact activation also poses a
problem in extracorporeal membrane oxygenation (ECMO), a
medical procedure in which an artificial lung system is used for
longer periods of time as a life support for patients with severe
cardiac and/or pulmonary failure20. The standard strategy for
suppressing contact system activation in extracorporeal circuits
relies on high doses of heparin, which also inhibit proteases of the
extrinsic and common coagulation pathway and thus bear an
inherent risk of bleeding21. Several strategies for suppressing
contact activation were established in experimental models, but
heparin remains the anticoagulation strategy of choice22. In a
recent study, Renné and co-workers showed that a human FXIIa-
inhibiting antibody, 3F7 (IC50= 13 nM), prevents clotting and
thrombosis in a cardiopulmonary bypass system in rabbits
without increasing therapy-associated bleeding14, indicating the
usefulness of targeting FXII.
FXII is implicated in several other medical conditions23,
including hereditary angioedema (HAE)24, reperfusion injury25,
Alzheimer’s disease26,27, and multiple sclerosis28, meaning that
potential FXIIa inhibitors could be used in a variety of treatments
not limited to thrombosis prevention. In Type III HAE, for
example, a mutation in FXII facilitates its activation, leading to
excessive bradykinin release that causes edema29. An improved
variant of the above-mentioned FXIIa inhibitory antibody 3F7
has entered a phase I clinical evaluation for the treatment of
HAE30.
While high-affinity protein-based FXIIa inhibitors were suc-
cessfully generated over the last years31, the development of
synthetic, small-molecule inhibitors has been more challenging.
Small molecules have a number of strengths that make them
attractive for drug development, including a uniform composi-
tion, efficient tissue penetration, high stability, low immunor-
eactivity, and ease of production by chemical synthesis. The best
small molecule FXIIa inhibitors reported to date are the coumarin
derivative 44 (IC50= 4.4 μM)32 and H-D-Pro-Phe-Arg-chlor-
omethylketone (PCK; IC50= 0.18 μM)10. While they have proven
to be useful as research compounds in FXIIa inhibition studies,
their covalent inhibition mechanism and their moderate potency
and selectivity limit their drug development potential.
We recently identified high-affinity FXIIa inhibitors based on
cyclic peptides using phage display, including the bicyclic peptide
FXII618 (Ki= 8.1 nM)33. In previous work, the substitution of
individual amino acids in FXII618 to unnatural ones further
improved the affinity34,35, though due to their limited binding to
animal FXIIa homologs and low proteolytic stability in plasma,
these particular inhibitors could not be evaluated in vivo. For this
reason, we describe herein the further improvement of the inhi-
bitor to achieve sub-nanomolar potency towards human, mouse,
and rabbit FXIIa, and we enhanced the stability in plasma to
several days (half-life in human plasma ex vivo). These properties
allowed for the pre-clinical evaluation of the inhibitor in two
animal models. This work shows that synthetic FXIIa inhibitors
can be developed to efficiently prevent thrombosis in mice and
suppress coagulation in artificial lungs in rabbits without
increasing the risk of bleeding.
Results
Engineered macrocycle inhibits FXIIa with sub-nanomolar
affinity. In a previously developed FXII inhibitor, FXII618, we
showed that the N-terminal arginine (Arg1) is rapidly cleaved by
plasma proteases (t1/2 around 4 h in human plasma), causing a
40-fold reduction in the Ki of the inhibitor34. When Arg1 was
substituted with diverse unnatural amino acids, the stability could
be improved at the price of a weaker inhibition, wherein amino
acids with positively charged side chains showed the smallest
affinity losses34. In a new attempt, we replaced Arg1 with a panel
of di-peptides that could potentially reach a larger surface area on
FXIIa to form productive interactions (Fig. 1a, Supplementary
Table 1). Both amino acids in the di-peptides were D-amino acids
to prevent proteolysis, and one of the two was D-Arg to maintain
a positive charge. To avoid extensive purifications for the initial
screening tests, we developed a synthesis and screening approach
based on coumarin-labeled peptides to compare the crude
activities, as described in detail in the Methods. A stability assay
showed that the di-peptides based on D-amino acids were resis-
tant to proteolysis, prolonging the plasma half-life around five-
fold to 20 h (Supplementary Fig. 1), and several di-peptides
improved the Ki values around two-fold over FXII618 (Fig. 1a).
The best inhibitor, Arg1→D-Arg-D-Ser (FXII850) was synthe-
sized without the coumarin label and showed a Ki of 5 nM,
which was a 1.6-fold improvement compared to FXII618 (Ki=
8.1 ± 0.7 nM; Fig. 1b and c, Supplementary Fig. 2). We also tested
a panel of diverse amino acid substitutions for Arg8, a position in
FXII618 that had not been systematically optimized, using the
same screening strategy based on coumarin-labeled peptides
(Fig. 1a, Supplementary Table 1). The substitution Arg8→His
(FXII851) did not affect the Ki of human FXIIa though had a clear
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effect on mouse FXIIa inhibition, with Ki values of 6.5 nM and
36 nM, for human and mouse respectively, which corresponded
to 1.2- and 2.4-fold improvements over FXII618 (Fig. 1b and c,
Supplementary Table 2).
We next combined the beneficial amino acid substitutions
identified in this work, the Arg1→D-Arg-D-Ser (FXII850) and
Arg8→His (FXII851) with the two previously identified substitu-
tions, Arg11→(S)-β3-homoarginine (βhArg; FXII700; Ki= 1.5 ±
0.1 nM)35 and Phe3→4-fluorophenylalanine (Phe4F; FXII800;
Ki= 0.84 ± 0.03 nM)34 (Fig. 1b and c, Supplementary Table 2). In
addition, we deleted the C-terminal Arg13 that did not contribute
to the binding affinity. The resulting inhibitor, FXII900, blocked
human and mouse FXIIa with Ki values of 0.37 ± 0.04 nM and
0.45 ± 0.11 nM, respectively, and was thus substantially more
potent than any of its precursors (Fig. 1c). This final inhibitor
could be efficiently synthesized in gram-scale by solid-phase
peptide synthesis of the linear precursor and subsequent
macrocyclization of the crude peptide with the 1,3,5-triacryloyl-
1,3,5-triazinane linker (TATA). Only a single HPLC purification
step was required to obtain > 95% pure product with an isolated
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yield greater than 50% (Supplementary Fig. 3). We had previously
developed a structural model of the precursor peptide FXII618
bound to FXIIa, in which we could determine with high
confidence the positions and interactions of the amino acids
Phe3 to Pro633. The newly identified beneficial amino acid
substitutions lie outside this region and we could thus not use the
model to rationalize the molecular basis of the achieved affinity
enhancements.
Finally, a specificity profiling against a panel of homologous
plasma proteases was performed to indicate any off-target
interactions that would occur in physiological conditions. Activity
assays against this chosen panel in the presence of the inhibitor
showed that FXII900 is highly selective (Fig. 1d, Supplementary
Table 3). All physiologically relevant proteases displayed 100,000-
fold or higher selectivity (Ki values > 40 μM), with only trypsin
showing any significant inhibition, which occurred at low
micromolar concentrations (Ki= 1.46 μM).
FXIIa inhibitor is stable in human plasma for several days. To
measure the stability of the inhibitor in plasma, FXII900 was
incubated in human plasma at 37 °C for extended time periods
and then the remaining FXIIa inhibitory activity was quantified
(Fig. 1e). Mass spectrometric analysis of the various plasma
samples showed only FXII900 and no degradation products,
though the quantity of the intact inhibitor decreased over time
(Fig. 1f, right panel). This suggested that after an initial cleavage
event, the inhibitor was rapidly degraded and, therefore, the
cleavage products were not detectable. Even so, the half-life of
FXII900 was 128 h, around 25-fold longer than that of FXII618. It
was also much longer than that of FXII850 carrying only the
Arg1→D-Arg-D-Ser modification (t1/2= 18.5 h; Fig. 1e), indi-
cating that more than one of the introduced mutations con-
tributed to the improved stability. To identify which of the
modifications was most important for stability, we individually
reverted the amino acid substitutions (Supplementary Fig. 4 and
Supplementary Table 4) and retested the variants, revealing that
the Arg11→βhArg substitution contributed the most to the sta-
bility improvement (Supplementary Fig. 5).
FXII900 efficiently inhibits the intrinsic coagulation pathway
ex vivo. To assess the ability of FXII900 to block FXII-driven
blood plasma coagulation and to further evaluate its selectivity,
we performed coagulation tests to measure activated partial
thromboplastin time (aPTT) and prothrombin time (PT). aPTT
and PT measure the time until coagulation upon initiation of the
intrinsic and extrinsic pathways, respectively, meaning that
selective FXIIa inhibition would prolong aPTT but not PT, and
results are reported in terms of the concentration of the tested
compound required for a 1.5x increase in coagulation time
(EC1.5x). FXII900 prolonged aPTT in human plasma with an
EC1.5x of 0.79 μM, thus 4.3-fold better than its precursor FXII618
(EC1.5x of 3.4 μM; Fig. 2a). FXII900 did not affect PT, even at the
highest concentration tested (120 μM), confirming the selectivity
for the FXIIa target (Fig. 2b). The inhibitor also prolonged the
aPTT in plasma of all other species, namely mouse (EC1.5x= 2.9
μM), rabbit (EC1.5x= 0.102 μM), and pig (EC1.5x= 12.2 μM),
wherein the potency varied significantly (Fig. 2a). For rabbit
plasma, we observed a strong prolongation of aPTT at low
inhibitor concentrations and a sharp transition to a maximal
effect. This pattern was previously seen for antibody-based FXIIa
inhibitors tested in rabbit plasma14, and we thus expected that
this was a rabbit plasma-specific phenomenon and not based on a
particularly strong affinity for rabbit FXIIa. The inhibitor did not
prolong PT in any of the three animal plasma tested (Fig. 2b).
To assess if FXII900 prolonged aPTT in the plasma of the four
species to different extents due to varying Kis for the various FXII
orthologues, we cloned and expressed rabbit and pig FXII because
they were not commercially available (Supplementary Figs. 6 and
7) and tested their inhibition by FXII618 and FXII900 (Fig. 2c).
These experiments, described in detail in the Supplementary
Information, showed that the FXII orthologues were inhibited
with different strengths and that the extent of aPTT prolongation
correlated with FXII inhibition (Ki).
Pharmacokinetics in mice, rabbits, and pigs. We assessed the
pharmacokinetic properties in three species, mice, rabbits, and
pigs, because suitable models for thrombotic diseases are available
for these animals. In mice, we determined the pharmacokinetics
following subcutaneous administration (5 mg kg−1, n= 3, dif-
ferent mice for each time point). FXII900 reached a plasma
concentration of around 1 μM after 3 min and remained above
this concentration for 30 min as determined by LC-MS (Fig. 3a,
upper panel). The aPTT was prolonged as expected based on the
plasma concentrations; namely, it was extended by two-fold at 15
min and remained prolonged by over 1.5-fold until 30 min
(Fig. 3a, lower panel).
In rabbits, we determined the pharmacokinetic properties for
intravenous and subcutaneous administration. Upon intravenous
administration (n= 3, 3.7 mg kg−1), FXII900 showed an elimina-
tion half-life of 12 ± 2 min (Fig. 3b, upper panel; pharmacokinetic
parameters provided in Supplementary Table 5). The aPTT was
initially more than eight-fold prolonged and remained more than
three-fold prolonged for the entire time monitored (40 min;
Fig. 3b, lower panel). When applying the same dose subcuta-
neously (n= 4, 3.7 mg kg−1), the peptide remained in a narrower
concentration range, staying above 100 nM and below 300 nM for
between 10 and 80 min after administration (Fig. 3c, upper
panel). The aPTT with the subcutaneous administration was
prolonged by more than 2-fold for 40 min (Fig. 3c, lower panel).
Fig. 1 Improving affinity and stability of bicyclic peptide FXIIa inhibitor. a Amino acids Arg1 and Arg8 of FXII618 were individually substituted to two
D-amino acids or natural amino acids, respectively. The relative Ki values for human and mouse FXIIa are indicated as compared to the lead peptide
FXII618. Average values of two measurements are shown for peptides with improved affinity. b Schematic representation of the lead peptide FXII618.
Amino acid substitutions that improve the activity and/or stability are indicated. c Inhibition of human FXIIa by FXII618, variants of FXII618 containing a
single amino acid substitution, and FXII900 in which four beneficial modifications were combined and Arg13 was deleted. Residual FXIIa activity was
determined in two (FXII850, FXII851), three (FXII618, FXII700, FXII800) or five (FXII900) independent measurements. Mean values are indicated. For
inhibitors that were tested three or five times, data are presented as mean ± SD. d Specificity profiling of FXII900. Residual activities of human FXIIa and
ten homologous human proteases were measured. Inhibition of FXII was determined in five, plasmin and APC in three, and all other proteases in two
independent measurements. Means values are indicated. e Proteolytic stability of FXII900 and two precursors. Bicyclic peptide was incubated in human
plasma at 37 °C for the indicated time periods, and the remaining inhibitor activity was quantified in a FXIIa activity assay using fluorogenic substrate. Two
independent measurements were performed for FXII850 and FXII900, and four for FXII618. Means values are indicated. f Proteolytic stability of FXII618
and FXII900. Bicyclic peptide was incubated in plasma at 37 °C for the indicated time periods and analyzed by LC-MS. Total ion count (TIC) is shown.
Source data of a, c–e are provided in a Source data file.
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We further determined the pharmacokinetics of FXII900 in pigs,
as this species offers models for indications in which FXII plays a
role, such as ischemic reperfusion injury25,36. After intravenous
administration (n= 3, 4mg kg−1), the inhibitor reached a maximal
concentration of around 7 μM and was cleared with a t1/2 of 36 ± 5
min (Fig. 3d, upper panel). The clearance rate and volume of
distribution were 11.8 ± 1.8 ml kg−1 min−1 and 610 ± 140ml kg−1
(Supplementary Table 6). In all the studies performed with the
three species, we did not observe any signs of toxicity or other
adverse effects.
FXII900 inhibits ferric chloride-induced thrombosis in mice.
We next evaluated the thromboprotective properties of FXII900
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in a ferric chloride (FeCl3)-induced thrombosis mouse model.
When applied directly onto the blood vessels, FeCl3 induces
thrombosis by aggregating the red blood cells, which in turn
activates platelets at the application site37–39. To test the ability of
our compound to protect against thrombosis in this model,
FXII900 or an inactive control peptide FXII901 were adminis-
tered subcutaneously to two groups each containing 10 mice
(5 mg kg−1). The negative control FXII901 is a variant of FXII900
with three modifications (Phe4F3→Phe, Arg4→Ala, βhAr-
g11→Arg) that reduce its inhibitory constant 100,000-fold for
FXIIa (Ki= 39 ± 14 μM; Supplementary Fig. 8). A solution of
7.5% FeCl3 was applied to the mesenteric arterioles and the blood
flow was monitored by intravital microscopy for 25 min. Mice
that were injured by FeCl3 could be clearly identified due to a
speckled pattern that supposedly represented an accumulation of
platelets (Fig. 4a)40. Seventeen out of the 20 mice showed this
pattern (nine treated, eight control) and were taken for further
analysis (Supplementary Figs. 9 and 10). The arterioles of the
mice receiving the inactive control peptide FXII901 rapidly
formed clots, and in a majority of the animals, the vessels were
completely occluded after around 10 min, as exemplified in the
lower micrographs in Fig. 4a and shown for all mice in Supple-
mentary Fig. 9. The time point and extent of clot formation
observed for the control peptide were as expected based on pre-
vious studies in which vessels of non-treated mice were exposed
to 7.5% FeCl341. In contrast, mice that were treated with the
inhibitor FXII900 showed only the characteristic speckled pattern
with the occasional formation of a blood clot (Fig. 4a, upper
micrographs; Supplementary Fig. 10). In this group, no complete
occlusion was observed. We quantified the anticoagulant effect of
FXII900 by comparing the rates for both clot formation (a clearly
visible blood clot; Fig. 4b, left panel) and blood vessel occlusion (a
blood clot with a diameter of the blood vessel; Fig. 4b, right
panel). Of the eight mice receiving the control peptide, seven
showed blood clotting and five showed full-vessel occlusion. In
contrast, in the FXII900-treated mice, only three showed blood
clotting, and in no mice were the vessels fully occluded (p for chi-
squared test= 0.02 and 0.005, respectively). In addition, the few
mice in the treated group that showed signs of coagulation
developed these blood clots on average around 10min later than
the control group (p for chi-squared test= 0.006; Supplementary
Table 7).
Repeating the experiment with a 5-fold higher dose of FXII900
(n= 8, 25 mg kg−1) and the negative control FXII901 (n= 9,
25 mg kg−1) gave comparable results to the lower dose, with no
further delay in coagulation or reduction in the rate of clot
formation (Fig. 4b; intravital microscopy for 20 min; by mistake
5 min shorter than in the experiment with lower dose). In this
repeat study, a positive control using the current gold-standard
drug heparin was added for comparison (n= 10, 200 IU kg−1). In
this control group, more mice showed blood clotting (six) and
vessel occlusion (one) than in the two groups treated with
FXII900 (Fig. 4b).
Mice treated with FXII900 have a normal hemostatic capacity.
We assessed the bleeding propensity of mice treated with the
higher of the two doses of FXII900 used in the above ferric
chloride-induced thrombosis study (25 mg kg−1, SC) using a tail
transection model (tail transection at 2 mm from the tail end,
diameter > 1 mm; n= 6). As positive and negative controls, we
treated mice with PBS (n= 6) and heparin (200 IU kg−1, IV, n=
6). We placed the tails into a tube with warmed PBS and mea-
sured the time of bleeding and the volume of blood lost. Mice
injected with heparin bled essentially continuously throughout
the monitored 30min period, which is similar to previous
reports41 and showed either a small (3 mice) or large loss of blood
(3 mice). Given the heterogeneous result for the blood loss, we
performed the heparin control with four additional mice, which
showed medium to high blood loss. Mice treated with the FXIIa
inhibitor showed an average bleeding time of 10 min and
blood loss of 21 μl, which was comparable to the PBS-treated
mice (average bleeding time: 7 min, average blood loss: 34 μl) and
the FXII901 control (Fig. 4c, Supplementary Fig. 11), which
indicated that the FXIIa inhibitor does not affect the hemostatic
capacity.
FXII900 provides bleeding-free anticoagulation in artificial
lungs. To test the clinical potential of FXII900 for inhibiting
FXII-driven coagulation in ECMO, we tested the inhibitor in an
artificial lung rabbit model. New Zealand White rabbits were
anesthetized, either treated intravenously with FXII900 (n= 4,
2 mg kg−1 bolus and 0.075 mg kg−1 min−1 infusion for four
hours), left untreated (n= 3), or treated with heparin for com-
parison (n= 2, infusion of 60 IU h−1 and rate adjustments to
maintain ACT within a clinical range of 220–300 s), and were
mounted for a 4-h period to a veno-venous ECMO configuration
using a polymethylpentene (PMP) fiber artificial lung system.
Treatment with FXII900 prolonged the coagulation parameters
aPTT and activated clotting time (ACT) around 10-fold during
the entire course of the experiment. This was to a much larger
extent than those for heparin, which were prolonged 1.5 and 2-
fold, the range recommended for heparin anticoagulation (Fig. 5a
and b). For most aPTT measurements using FXII900, no
coagulation was observed at 240 s, the maximal aPTT value
measured with this device (Supplementary Fig. 12a). In untreated
rabbits, the coagulation times remained at baseline values of
around 20 s (aPTT) and 170 s (ACT) throughout the experiment.
Because increased pressure at the inlet of the artificial lung
indicates clogging that can be caused by blood coagulation, we
measured the resistance of the artificial lung, indicated by the
difference in pressure at the inlet and outlet of the lung divided by
the flow. In all rabbits treated with FXII900, the resistance
remained at the baseline of 50 mmHg L−1 min−1 during the
entire experiment, except for one rabbit in which the resistance
started to increase strongly after two hours at baseline (Fig. 5c
and Supplementary Fig. 12c). This was in stark contrast to the
untreated animals in which the resistance increased in the first
hour and doubled for all rabbits from 50mmHg L−1 min−1 to
100 mmHg L−1 min−1 during the course of the experiment.
Because excessive bleeding is a major concern with standard
anticoagulation in ECMO systems, we analyzed if FXII900
affected the hematological parameters of bleeding time and
platelet count. Rabbits treated with the inhibitor showed
completely normal bleeding times throughout the experiment
(4–5 min; Fig. 5d and Supplementary Fig. 12d). In contrast, the
group treated with heparin at a clinically relevant dose showed 2-
fold prolonged bleeding times (5–10 min) at all the time points
measured (Fig. 5d and Supplementary Fig. 12d). The platelet
count was essentially the same in the three groups, decreasing
around two-fold from an initial level of 2 × 108 cells per ml
(before connecting the lung) and remaining constant over the
entire course of the experiment (Fig. 5e and Supplementary
Fig. 12e). Analysis of the artificial lungs at the end of the
experiment showed that the inhibitor- and heparin-treated
rabbits had a reduced amount of clotted blood. The volume of
the clot in relation to the device volume was 10 ± 6% for the
FXII900-treated rabbits, which was significantly smaller than that
of untreated rabbits (37 ± 10%; p= 0.03), but it was slightly larger
than that of the heparin-treated rabbits (5%; Fig. 5f and
Supplementary Fig. 12f).
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Discussion
Various protein-based inhibitors were developed that showed
that suppression of FXIIa activity provides efficient antic-
oagulation without increasing bleeding risks, though the devel-
opment of high-affinity small-molecule FXIIa inhibitors has been
lagging. Given the attraction of small, synthetic molecules as
therapeutics, in this work, we improved the binding affinity and
stability of FXII618, a peptide macrocycle FXIIa inhibitor that
was previously developed by phage display. The generated inhi-
bitor FXII900 blocks FXIIa with a Ki of 370 pM, shows 100,000-
fold selectivity over other plasma proteases, and is stable in
blood plasma.
The improvement of the binding affinity of FXII618 by 21-fold
and proteolytic stability by 25-fold was achieved by combining
random screening and rational design strategies. Two amino acid
substitutions that enhance the affinity and/or stability of the
inhibitor were identified by screening a panel of singly mutated
peptides, and were combined with two previously identified
beneficial mutations. Individual reversion of the amino acid
substitutions in FXII900 showed that each single one contributes
to improving the binding affinity and that the modifications of
Arg1 to D-Arg-D-Ser and Arg11 to βhArg are the main ones that
improve the stability. The higher binding affinity translates into a
prolongation of the aPTT in all species tested, with the EC1.5x
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Fig. 4 Thromboprotection of FXII900 in mice and effect on bleeding. a Intravital fluorescence microscopy images showing mesenteric arterioles in which
thrombosis was induced by topical application of FeCl3 (7.5%, 1 min). Platelets were fluorescently labeled with Rhodamine 6G for visualization.
Representative images are shown for two mice, one treated with FXII900 (upper panels) and one treated with inactive control peptide FXII901 (lower
panels) 15 min before the application of ferric chloride (5 mg kg−1, subcutaneous injection). Vessel walls at the FeCl3 application site are indicated with
yellow markers. Three distinct morphological changes, (1) a characteristic speckled pattern, (2) clot formation, (3) and vessel occlusion, are indicated.
Scale bar: 200 μm. b The percentage of mice showing either clot formation or full occlusion at different time points after ferric chloride application is
indicated over time (inhibitor FXII900: 5 mg kg−1, n= 9; 25 mg kg−1, n= 8; neg. control FXII901: 5 mg kg−1, n= 8, 25 mg kg−1, n= 9; heparin: n= 10). Clot
formation was defined as the appearance of an aggregate with a diameter larger than 10 μm. Full occlusion of the blood vessel was defined as a blood clot
having the same diameter as the blood vessel. c Blood loss and bleeding time of mice with 2 mm tail transections. Mice were treated 5min before clipping
the tail tips with the vehicle (PBS, IV, n= 6), heparin (200 IU kg−1, IV, n= 10), FXII900 (25mg kg−1, SC, n= 6) or FXII901 (25 mg kg−1, SC, n= 6). Mean
values and standard deviations are indicated. The significance for a prolonged bleeding time was assessed with an unpaired, one-tailed t-test. The p value is
indicated for significant results and n.s. stands for not significant. Mice treated with heparin showed either a small or medium-to-large loss of blood, and a
mean value is thus not indicated.
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improved 4.3-fold in human plasma and 10-fold in mouse
plasma. As expected, the EC1.5x values are much higher than the
Ki values because FXII needs to be inhibited nearly fully to pro-
long aPTT 1.5-fold (we estimate > 99%) while the Ki is by defi-
nition the concentration at which 50% of FXII is inhibited. The
much-enhanced potency in mouse plasma was of interest in view
of the planned pharmacologic study in mice. FXII900 did not
prolong PT at 120 μM at all, which contrasted with FXII618 that
prolonged the PT slightly at this highest concentration tested,
indicating that modification of the four amino acids had also
improved the selectivity of the inhibitor. The enhancement of
affinity, selectivity, and stability achieved in this work is owed
mostly to unnatural amino acids that could be incorporated due
to the synthetic nature of the inhibitor, which is an advantage
over protein-based inhibitors that need to be produced by
recombinant expression and do not easily allow the incorporation
of unnatural building blocks.
FXII900 is composed of nine natural amino acids, four non-
natural ones, and a central core structure that connects the side
chains of three cysteines. The inhibitor can be conveniently
synthesized by automated solid-phase peptide synthesis in large
quantities. All applied non-natural amino acids are inexpensive,
allowing for production of inhibitor for a moderate cost. Crude
linear peptide was cyclized efficiently by the chemical linker
TATA and only a single HPLC purification step was required to
obtain > 95% pure product with isolated yields greater than 50%.
We provide a supplementary figure that describes the exact
peptide sequence and the conditions recommended for peptide
cyclization, which may be used for ordering the peptide from
companies offering custom peptide synthesis (Supplementary
Fig. 3).
FXII900 is rapidly cleared upon intravenous administration,
most likely by renal filtration, as expected based on the small
size and the polar structure. The elimination half-life ranges from
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12 min in rabbits to 36 min in pigs. The prolongation of the aPTT
correlated with the PK data for all species. Based on allometric
scaling, the half-life in humans can be expected to be in the range
of one hour. No degradation products were detected in plasma
samples of all species, suggesting that the inhibitor fully resists
proteases in the blood circulation and that it is filtered out as an
intact molecule, which is in line with the high stability and long
half-life in plasma found ex vivo. Despite the fast clearance, a
single-dose injection of FXII900 prolonged the aPTT in mice and
rabbits for 30 min. The relatively short circulation time of these
small molecules, especially as opposed to protein therapeutics,
allows flexible adjustment of the duration for which the body is
exposed to the inhibitor in therapeutic applications. The phar-
macokinetic profile of FXII900 makes it attractive for acute dis-
ease treatment such as CPB, hemodialysis and ECMO, or
anticoagulation for short time periods after ischemic stroke or
surgery, wherein a patient is hospitalized and could be given
infusions of the inhibitor for the desired time period. For
hemodialysis applications, the inhibitor would potentially need to
be tethered to a large protein or polymer to prevent rapid removal
by the filtration unit. For controlling the activity of FXII over
several days, weeks or months, FXII900 is not suited and other
therapeutic modalities such as antibody-based FXII inhibitors or
antisense oligonucleotides are clearly better options. Given its
high proteolytic stability, FXII900 could potentially resist to some
extent proteases of the stomach and intestines, but due to the
multiple charges, it would unlikely be able to cross the gastro-
intestinal epithelium, preventing oral administration.
We evaluated the pharmacologic activity of FXII900 in a ferric
chloride-induced thrombosis mouse model. FXII-deficient mice
show strong reduction of coagulation in this model, indicating
that FXII plays a central role in this process8,9. We found that a
bolus injection of FXII900 efficiently protected mice from
thrombosis, while bleeding time and blood loss were not affected,
as assessed in a tail transection bleeding model. This was in strong
contrast to a control experiment with heparin (200 IU kg−1) in
which mice were constantly bleeding throughout the 30 min
period monitored and lost a large volume of blood. It is important
to say, however, that thrombosis in myocardial infarction,
ischemic stroke, or pulmonary embolism is more complex than in
the applied mouse thrombosis model, as thrombosis can also be
caused by triggers that are not dependent on FXII activation.
Independent of this, the results obtained show that a synthetic
FXIIa inhibitor can efficiently suppress coagulation in cases where
it is mediated via FXII activation.
Finally, we further tested if FXII900 could suppress the coa-
gulation activated by the membrane of artificial lungs using a
rabbit model. Heart-lung machines are used for heart surgery
because of the difficulty of operating on the beating heart such
that approximately half a million cardiac operations performed
per year in the US use CPB. Similar, more compact systems are
also used to support patients with cardiac and respiratory dys-
function, with more than 7000 patients treated annually with
extracorporeal life support42. The contact of blood with the
hydrophobic polymer surfaces found in these machines induces
FXII contact activation and thus coagulation. This coagulation is
currently suppressed using high doses of heparin, which bears
bleeding risks. An analysis of nearly 80,000 ECMO patients
showed that hemorrhage is the major adverse event in these
situations, with bleeding from surgical sites occurring in 6.3% to
29.3% of patients depending on the patient group42. Moreover,
both device thrombosis and patient bleeding lead to significant
increases in patient mortality43. We found that continuous
infusion of FXII900 efficiently prolonged the coagulation para-
meters ACT and aPTT over four hours and thus the entire course
of the experiment. The inhibitor reduced coagulation in an
artificial lung as measured by the resistance of the device, which
remained low and indicated reduced clogging by coagulation and
a reduction in the total volume of the blood clots in the device,
which was more than three-fold lower in treated rabbits.
Importantly, all rabbits treated with FXII900 showed normal
bleeding times. These findings indicated that a small molecule
FXIIa inhibitor is suitable for reducing blood coagulation in CPB.
While heparin may still be required to suppress coagulation
triggered through routes other than FXII, the application of a
small molecule FXIIa inhibitor may allow for a reduced heparin
dose, which would reduce the bleeding risks. In addition to its
role in thrombosis in ECMO and CPB, FXIIa initiates the
inflammatory kallikrein-kinnin system19. Bradykinin plasma
concentrations are largely elevated in CPB and ECMO patients,
so targeting FXIIa may provide an additional anti-inflammatory
benefit to these patients, to reduce or prevent adverse effects, such
as organ damage.
In conclusion, a synthetic FXIIa inhibitor with sub-nanomolar
affinity, high selectivity, and good stability has been developed
that allows for efficient anticoagulation in relevant animal disease
models without increasing bleeding risks, addressing several
concerns surrounding the current gold-standard treatment of
heparin. The synthetic nature and the small size allows for effi-
cient production of the compound. With its excellent binding
properties and stability as demonstrated herein, the inhibitor may
be readily applicable in its current form for acute procedures or
conditions associated with an increased risk of thrombosis, such
as CPB during heart surgery or ECMO without compromising
hemostasis at the wound site.
Methods
Study design. The objectives of this study were to improve the pharmacologically
relevant properties of a peptide macrocycle inhibitor of FXIIa, to assess the
pharmacokinetic properties of the resulting inhibitor in three species, and to
evaluate the inhibitor in two clinically relevant animal models. The inhibitor was
engineered by synthesizing variants of the lead peptide and testing their inhibitory
activity, specificity, and stability in various assays in vitro. Inhibitors showing
improved activities were prepared with greater than 95% purity and their activities
were tested at least in duplicate. The affinity of the final peptide FXII900 was
determined in quintuplicate from three different synthetic batches. The pharma-
cokinetic properties in mice, rabbits, and pigs were assessed by quantifying the
inhibitor in plasma samples using liquid chromatography and mass spectrometry,
and by measuring aPTT in plasma samples in duplicate or triplicate, as indicated.
The pharmacologic effects of the inhibitor were tested in a FeCl3-induced
thrombosis model in mice and in an artificial lung model in rabbits. In all animal
experiments, subjects were randomly assigned to groups.
Screening method based on coumarin-labeled peptides. In order to test the
inhibitory activity of peptides without prior purification, we developed the fol-
lowing method. Variants of the lead FXII618 peptide were synthesized with the
C-terminal amino acid Fmoc-β-(7-methoxy-coumarin-4-yl)-Ala-OH. The fluor-
ophore 7-methoxy-coumarin allowed precise quantification of the crude peptide.
After solid-phase peptide synthesis, cleavage, and ether precipitation, the peptides
were chemically cyclized and their Ki values were determined in a FXIIa activity
assay using a fluorogenic substrate. Peptides synthesized and characterized with
this strategy displayed an around 2.5-fold higher apparent Ki than analogous
HPLC-purified peptides without the tag. For example, the reference peptide
FXII618 carrying the coumarin amino acid had an around 2.5-fold weaker Ki (20 ±
3 nM) compared to the purified FXII618 without the tag (8.1 ± 0.7 nM). Despite the
difference, this method allowed for a comparison between peptides and the iden-
tification of the most active variants of FXII618. The best peptides from the screen
were synthesized without the coumarin label, purified, and characterized.
Plasma stability assays. Peptide (2 μl of 2 mM in H2O) was added to 398 μl of
citrated human plasma (Innovative Research) to obtain a final peptide con-
centration of 10 μM. The mixture was incubated in a water bath at 37 °C. At
different time points (0, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 h), samples of 30 μl were
removed, diluted to 200 μl with aqueous buffer (10 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 10 mM MgCl2, 1 mM CaCl2), and incubated for 20 min at 65 °C to inactivate
plasma proteases. The peptide/plasma samples were stored at −20 °C until the
residual inhibitory activity of the peptides was measured in a FXIIa inhibition
assay. For the activity assay, the peptide/plasma samples were centrifuged for 5 min
at 16,000 × g, serial two-fold dilutions of the supernatant were prepared (peptide
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concentration ranges from 0.5 nM to 0.5 μM), and the residual activity of 0.5 nM
human β-FXIIa was measured using 50 μM Boc-Gln-Gly-Arg-AMC substrate. IC50
values were derived from the fitted curve using an equation described in the
Supplementary Methods. Residual inhibition in % was calculated using the equa-
tion IC50,0h/IC50,xh*100, wherein IC50,0h is the functional strength of the inhibitor
at time point 0 and IC50,xh the functional strength of the inhibitor after one of the
different plasma incubation periods mentioned above.
Plasma degradation assays. Plasma stability and peptide cleavage sites were
assessed by incubating the bicyclic peptides in mouse plasma and analyzing the
products with an LC-MS system (LCMS-2020, Shimadzu). Peptide (2 μl of 2 mM in
H2O) was added to 48 μl of citrated mouse plasma (Innovative Research) to obtain
a final peptide concentration of 80 μM. The mixture was incubated in a water bath
at 37 °C. At different time points (0, 15, 24, 72, 96, 120, and 144 h), samples of 5 μl
were removed, mixed with 5 μl of 6 M guanidinium hydrochloride, and incubated
for 30 min at RT. Plasma proteins were precipitated by incubation with 200 μl of
ice cold EtOH and 0.1% (v/v) formic acid for 30 min and centrifuged at 9000 × g
for 20 min at 4 °C. The supernatant was evaporated in a Speedvac at 50 °C and
reduced pressure. The residue was dissolved in 40 µl of deionized water containing
0.1% (v/v) CHOOH and analyzed by LC-MS. The samples were analyzed using an
analytical C18 column (Phenomenex C18 Kinetex column, 50 × 2.1 mm, 2.6 μm,
100 Å) and a linear gradient of 5–35% solvent B (MeCN, 0.05% [v/v] CHOOH) in
solvent A (H2O, 0.05% [v/v] CHOOH) in 5.5 min at a flow of 1 ml per min. The
masses of the intact peptide and degradation products were measured on a single
quadrupole mass spectrometer in positive ion mode using electrospray ionization.
Peptides were quantified based on the absolute intensities of the detected mass
peaks (M3+ and M4+).
Cloning of vectors for expression of FXII in mammalian cells. The protein
sequences for human, rabbit and pig factor XII were taken from the following
database entries: human FXII: UniProtKB - P00748; rabbit FXII: NCBI RefSeq -
XP_008253687.1; pig FXII: UniProtKB - O97507. The sequences are shown in the
Supplementary Methods. DNA encoding the full-length proteins were ordered
from Eurofins Genomics. The codons in these sequences were optimized for
mammalian expression using the codon optimization tool from Integrated DNA
Technologies (IDT). In addition to the FXII gene, the ordered DNA sequences
encode a C-terminal GSGS-linker, a His6-tag and a stop codon, and they are
flanked by NheI (GCTAGC) and a HindIII (AAGCTT) restriction sites. The entire
DNA sequences are provided in the supporting materials. The DNA sequences
were cloned into the pEXPR-IBA42 vector downstream of a BM40 signal sequence
for secreted expression in mammalian cells. The ligated vector was transformed
into DH5 alpha electrocompetent E. coli cells. Plasmid DNA from single clones was
sequenced by Sanger sequencing.
Recombinant expression, purification, and activation of FXII. 1.5 mg plasmid
DNA was transfected into 500 ml CHO cells (Thermo Fisher Scientific) in cell
suspension culture using polyethylenimine (PEI). Cells were incubated for seven
days at 37 °C, 5% CO2 under shaking conditions. The cells were removed by
centrifugation and the secreted protein was purified from the supernatant using a
nickel-charged immobilized metal affinity chromatography (IMAC) column (5 ml
HisTrap FF Crude, GE Healthcare). The column was equilibrated with buffer
containing 15 mM imidazole, 100 mM NaCl, 20 mM Tris-HCl, pH 7.4. The pH of
the cell culture supernatant was adjusted to 8.0 using NaOH. The supernatant was
run through the column at a flow of 5 ml per min. The column was washed with 20
column volumes of equilibration buffer at a flow of 5 ml per min. The protein was
eluted with 500 mM imidazole, 100 mM NaCl, 20 mM Tris-HCl, pH 7.4 at a flow of
5 ml per min. The buffer was subsequently exchanged to 100 mM NaCl, 20 mM
Tris-HCl, pH 7.4 by three iterative steps of 10-fold dilution and 10-fold con-
centration using a 10,000 MWCO centrifugal concentrator. The concentration was
determined by measuring absorption at 280 nm (ε= 100,000). For the activation of
recombinant FXII, 10 μg protein was diluted to a total volume of 10 μl 100 mM
NaCl, 20 mM Tris-HCl, pH 7.4 and further diluted with 10 μl of 2-fold con-
centrated assay buffer (300 mM NaCl, 20 mM MgCl2, 2 mM CaCl2, 20 mM Tris-
HCl, 0.02% (v/v) Triton-X100, pH 7.4). Dextran sulfate 500 kDa (DXS500) was
added to a final concentration of 0.2 μg μl−1 and incubated for 1 hour at 37 °C. 5 μg
protein was analyzed by SDS-PAGE under reducing conditions.
Animal study authorization. All experiments in mice and pigs were conducted in
accordance with the terms of the Swiss animal protection law and were approved
by the animal experimentation committee of the cantonal veterinary service
(Canton of Berne, Switzerland). The pharmacokinetic studies in rabbits were
performed at Washington Biotech Inc. following ethical standards for animal
studies of the Office for Laboratory Animal Welfare (OLAW), a division of the US
Public Health Service as administered by the National Institutes for Health. The
extracorporeal circulation studies in rabbits were performed in compliance with the
Allegheny Health Network Institutional Animal Care and Use Committee. The
studies in rabbits were approved by the American Association for Laboratory
Animal Science (IACUC).
Pharmacokinetic study in mice. Mice for all experiments were kept at ambient
temperature (around 20 °C), around 60% humidity, half-day light/half-day dark
cycles, and in groups of 2–5 mice per cage. C57BL/6J wild-type mice (male,
10–20 weeks old, 25–30 g, Charles River) were injected subcutaneously over the
shoulders with 5 mg kg−1 of FXII900 (0.5 mg ml−1 in PBS, pH 7.4). The mice were
anaesthetized 3 min before the scheduled blood collection time point (40 mg kg−1
pentobarbital). An abdominal midline incision was performed and 450 μl of whole
blood was drawn from the inferior vena cava into a syringe containing sodium
citrate (50 µl 3.2% [w/v] sodium citrate). The mice were euthanized by cervical
dislocation. The blood was immediately processed to plasma by centrifugation for
10 min at 2000 × g and 4 °C, and stored at −80 °C. The concentration of FXII900 in
the plasma samples was determined by LC-MS as described below. Differenct mice
were used for each time point.
Pharmacokinetic study in rabbits. The pharmacokinetic properties of FXII900
applied intravenously were determined as follows44. Female New Zealand White
rabbits (10–20 weeks old) were injected with 3.7 mg kg−1 FXII900 dissolved in 1 ml
PBS, pH 7.4 via the ear vein. Blood samples (2.7 ml) were collected at different time
points into sodium citrate tubes (BD Vacutainer ref # 363083) and immediately
processed to plasma by centrifugation at 1400 × g for 15 min. The concentration of
FXII900 in the plasma samples was determined by LC-MS as described below. The
pharmacokinetic properties of FXII900 applied subcutaneously were determined as
follows. Female New Zealand White rabbits (2.5–2.9 kg) were injected sub-
cutaneously over the shoulders with 3.7 mg kg−1 of FXII900 dissolved in 1 ml PBS
pH 7.4. Blood samples (1.8 ml) were collected at different time points into sodium
citrate tubes (BD Vacutainer ref # 363080) and immediately processed to plasma by
centrifugation at 1800 × g for 10 min. The plasma was stored at −80 °C. The
concentration of FXII900 in the plasma samples was determined by LC-MS as
described below.
Pharmacokinetic study in pigs. Swiss large white pigs, both sexes, 3–4 months old
(30 ± 5 kg) were anesthetized and prepared following procedures used to study
myocardial ischemia/reperfusion injury45. In this procedure, the ACT is monitored
and 2500 IU of heparin are injected when ACT values fall below 180 s. Pigs were
injected intravenously with 4 mg kg−1 of FXII900 dissolved in 1 ml PBS, pH 7.4.
Blood samples (2.9 ml) were collected at different time points into sodium citrate
tubes (Sarstedt S-Monovette ref # 04.1902.001) and immediately processed to
plasma by centrifugation at 1400 × g for 15 min at RT. The concentration of
FXII900 in the plasma samples was determined by LC-MS as described below.
Quantification of inhibitor in plasma samples. The concentration of FXII900 in
the plasma samples was quantified based on peak intensities of total ion current
(TIC) chromatograms acquired by LC-MS (LCMS-2020, Shimadzu). To 15 μl of
plasma sample, 1 μM of internal standard peptide and 5 μl of 6 M guanidinium
hydrochloride solution were added and mixed. Plasma proteins were precipitated
by the addition of 400 µl of ice cold ethanol (99.9% [v/v] EtOH, 0.1% [v/v] TFA)
and incubated on ice for one hour. Precipitate was removed by centrifugation
(9000 × g, 20 min, 4 °C) and the supernatant dried by centrifugal evaporation under
vacuum. Dried samples were dissolved by sequentially adding 2 μl of DMSO and
18 μl of H2O containing 0.1% (v/v) CHOOH and analyzed by LC-MS. The samples
were analyzed using an analytical C18 column (Phenomenex C18 Kinetex column,
50 × 2.1 mm, 2.6 µm, 100 Å) and a linear gradient of 5–30% solvent B (MeCN,
0.05% [v/v] CHOOH) in solvent A (H2O, 0.05% [v/v] CHOOH) in 4.5 min at a
flow of 1 ml per min. The mass was measured on a single quadrupole mass
spectrometer in positive ion mode using electrospray ionization. Peptides were
quantified based on the absolute intensities of the detected mass peaks (M3+ and
M4+).
FeCl3 injury thrombosis model in mesenteric arterioles in mice. A model of
thrombosis in mesenteric arterioles using intravital microscopy was performed
according to Angelillo-Scherrer A. et al.46 with minor modifications. C57BL/6J
wild-type mice (male, 10–20 weeks old, 25–30 g, Charles River) were injected
intravenously with Rhodamine 6G (100 μl, 1 mM, ACROS Organics product
41902) to fluorescently label the platelets and leucocytes. The mice were injected
subcutaneously over the shoulders with FXII900 (5 or 25 mg kg−1, 0.5 mg ml−1 in
PBS, pH= 7.4) or the negative control FXII901 (5 or 25 mg kg−1, 0.5 mg ml−1 in
PBS, pH= 7.4), or intravenously (retro-orbital) with 200 IU kg−1 heparin, and
subsequently anesthetized with ketamine (80 mg kg−1) and xylazine (16 mg kg−1)
via intraperitoneal injection. An abdominal midline incision was made to expose
the mesenteric arterioles which were imaged by intravital microscopy using a
Mikron IVM500 microscope (Mikron Instruments) coupled with a 50W mercury
lamp (HBO 50 microscope illuminator, Zeiss) attached to combined blue (exciter
455DF70, dichroic 515DRLP, and emitter 515ALP) and green (exciter 525DF45,
dichroic 560DRLP, and emitter 565ALP) filter blocks. Thrombus formation was
induced by the application of a 1 × 2 mm filter paper saturated with FeCl3 solution
(7.5% [w/v], Roth, art no 5192.1) onto the blood vessel for 1 min. The blood flow,
clot formation and vessel occlusion were monitored for 20 or 25 min wherein
images were recorded every minute using a digital video cassette recorder (DSR-11,
Sony) and analyzed using ImageJ software (version 1.52). Mice were euthanized by
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final bleeding and cervical dislocation. Time to clot formation and full occlusion of
the blood vessel were determined as follows. Clot formation was defined as the
formation of a clear aggregation with a diameter of around 10 µm or larger.
Occlusion was defined as a clot covering the full diameter of the vessel. Mice
showing no speckled pattern at the site of FeCl3 application were assumed to be not
injured at the blood vessel and were excluded from the analysis.
Tail bleeding time and volume. Mice (8- to 10-week-old) were anesthetized with
pentobarbital (50 mg kg−1, IP), treated with PBS (IV, retro-orbital), 200 IU kg−1
heparin (IV, retro-orbital), 25 mg kg−1 FXII900 (SC) or 25 mg kg−1 FXII901 (SC),
and put on a 37 °C heating pad. After 5 min, the distal tail was transected at 2 mm
with a disposable surgical blade, and the diameter measured to confirm that it is >
1 mm. The tail was placed in a 50 ml falcon tube filled with phosphate-buffered
saline (warmed to 37 °C) and the bleeding time was recorded. The total blood loss
was determined by measuring the absorption at 540 nm.
Artificial lungs. Mini-lungs were created that allowed for blood exposure to the
fibers in the artificial lung, but for construction simplicity, do not transfer gas.
Polymethylpentene (PMP) fiber (3 M) with 50% porosity, a 380 μm outer diameter,
and two layers at 30° cross angles were cut into 1.78 × 1.78 cm squares. Five of these
layers were put together, making sure the fibers all ran in the same direction, and
they were sealed together into a fiber bundle using a hot plate on each side of the
square sheets. These fiber bundles were melted such that they had a 1.57 × 1.57 cm
square frontal area perpendicular to the flow. Eight 5-layer “chiclets” were placed
together to make up the fiber bundle of one mini lung device, giving a final surface
area of 263 cm2. These fiber bundles were placed in a square plastic housing of 3.05
cm in length, making sure that the fiber bundles fit tightly in the device to prevent
shunting around the fiber bundle. This housing was attached to plastic end caps
that were placed on each end with a 1/8″-barbed tube fitting for 3/16″-ID tubing to
allow the device to be connected to tubing in the circuit. These end connectors
were coated with Teflon tape before connecting them to the plastic end caps to
prevent leakage. The device was held together with two screws going from end cap
to end cap. The entire device was secured with silicone to eliminate leakage. The
silicone was left to dry for 24 h, and the device leak tested as follows. Filtered
deionized water was run through the device to check for leaks within the device. If
no leaks were found, the device was left to dry with filtered air running through the
device for 24 h.
Extracorporeal circulation in rabbits. New Zealand white rabbits of 3.2–4.2 kg
(Charles River) were anesthetized via intramuscular injections of ketamine
(30 mg kg−1) and xylazine (5 mg kg−1). One of the ear veins was catheterized
via a 24G winged catheter, and the rabbits were intubated with a 3.0 endotracheal
tube. The animals were kept anesthetized throughout the four-hour experiment
via inhaled isoflurane (2%) and were ventilated with a peak inspiratory pressure
(PIP) of < 20 cmH2O, positive end expiratory pressure of 5 mmHg, tidal volume of
4–6ml kg−1, and a respiratory rate of 22–60 breaths per min. Tidal volume and
respiratory rate were adjusted to maintain normal arterial blood gases and the listed
PIP. Phenylephrine was applied intravenously at a rate of 0.5–5 μg kg−1 min−1 to
maintain blood pressure. For monitoring blood pressure and collecting blood
samples, the rabbits’ right or left carotid arteries were cannulated using a 16-gauge
angiocatheter (Becton Dickinson) and were secured with silk ties. The device and
circuit were first primed with filtered CO2 and then with saline (NaCl, 0.9% [w/v])
containing solumedrol (30mg kg−1). At this point, rabbits of the inhibitor-treated
group were injected with 2 mg kg−1 of FXII900 as a 2 mM solution in PBS (pH 7.4)
via the ear vein and the circuit was connected to the rabbits via a venous/venous
ECMO configuration using a 14-gauge angiocatheter (Becton Dickinson) and a
6″ pressure tubing that was cut to length from a 24″ pressure tubing (Edwards
Lifesciences) in the right and left internal jugular veins, respectively. The circuit was
placed in a roller pump (Cobe), and the blood flow was set to 45 ml per min. After
connecting the extracorporeal circuit, rabbits of the inhibitor-treated group were
infused with 0.075 mg kg−1 min−1 FXII900 via the ear vein for the entire duration
of the study. Rabbits treated with heparin were initially infused with
60 IU h−1 (100 IUml−1) starting before connection to the circuit. The drip rate was
adjusted based on the following nomogram to maintain the ACT in a range between
220 and 300 s. ACT > 320 s: decrease infusion rate by 12 IU h−1, 320 s > ACT >
300 s: decrease infusion rate by 6 IU h−1, 300 s > ACT > 220 s: maintain heparin
infusion rate, 220 s > ACT > 200 s: increase infusion rate by 6 IU h−1, 200 s > ACT >
180 s: increase infusion rate by 12 IU h−1, ACT < 180 s bolus 100 U (1ml). After
four hours, the animals were euthanized by potassium chloride (2 mg kg−1, IV). At
the end of the experiment, 5 ml of heparin was run through the artificial lung while
it was still connected to the rabbits. Then the circuit was removed, and the device
was washed with saline carefully so that no clot shedding occurred. Saline was run
through the device until the drained portion the effluent was clear. Clot volume was
measured by measuring the volume of the device prior to the experiment and again
at the end of the experiment after washing. This was done by completely
filling the device with saline and recording this amount of saline as the device
volume. The difference between the beginning and ending volume was determined
to be the clot volume. From the clot volume, the percent of clot within the device
was calculated.
Data acquisition during extracorporeal circulation. Platelet and white blood cell
counts, hematocrit, arterial blood gases (ABG), ACT, aPTT, fibrinopeptide A
(FPA), device resistance, and bleeding time were measured prior to circuit
attachment and at 10, 30, 120, and 240 min following the initiation of ECMO. For
the platelet counts, a syringe with 0.05 ml of 3.2% sodium citrate (w/v) was used to
draw 0.45 ml of blood for a total volume of 0.5 ml. This was then centrifuged at
60 × g for 10 min, and 20 µl of the plasma was placed in 20 ml of ISOTON® diluent
and counted using a Coulter Counter (Beckman Coulter, Inc. Brea, CA) with a
50 μl aperture tube. For counting, cells were considered platelets if their diameters
were 1.8–5.6 μm. For white blood cell counts, 40 μl of whole blood was placed in
20 ml of the ISOTON® diluent. Six drops of ZAP-OGLOBIN lysing solution were
added to the mixture and mixed gently. This was allowed to sit for 2 min. The
white blood cells were also counted using the Coulter Counter (Beckman Coulter)
with a 50 μl aperture tube where any particle above 3.6 μm in diameter was con-
sidered a white blood cell. Arterial blood gases were measured by drawing 0.4 ml of
blood into a heparinized syringe and run using an arterial blood gas analyzer
(ABL800 FLEX, Radiometer). The ACT and hematocrit were measured by col-
lecting 0.5 ml of blood. The ACT was measured using a Hemochron analyzer with
tubes containing glass beads as the activator. The hematocrit was measured via
capillary centrifugation. For aPTT measurements, blood samples (1.8 ml) were
collected at different time points into tubes containing sodium citrate (0.2 ml, 3.2%
[w/v] sodium citrate) and immediately processed to plasma by centrifugation at
2000 × g for 15 min at 4 °C. The samples were then analyzed as described above. All
platelet counts, WBC counts, FPA, and FXIIa levels were corrected for hemodi-
lution by adjusting the raw values based on the hematocrit. The inlet and outlet
pressure and blood flow rate were measured using a Biopac system (Aero Camino
Goleta, CA) and pressure transducers at the inlet and outlet of the device (Edwards
Lifesciences), and the resistance was calculated with the standard R= (Pi− Po)/Q
where Pi is the inlet pressure in mmHg, Po is the outlet pressure in mmHg, and Q is
the flow in Lmin−1. The bleeding time was measured by cutting small incisions of
4–5 mm at different sites of the right or left ear in each animal. Blood from the
incision was removed with gauze every 30 s, and the time until the bleeding
stopped was measured.
Statistical analysis. For all experiments, mean values are indicated for indepen-
dent replicates. For experiments performed in triplicate or more, means and
standard deviations are indicated. All statistical analyses were performed using
GraphPad Prism (version 5) or Microsoft Excel software (version 2016). A chi-
squared test was used to determine whether mice were protected against clot
formation and full occlusion in the FeCl3 thrombosis model. A one-tailed student’s
t-test was applied to determine the significance of the difference in the time until
clot formation occurred between the two groups. A one-tailed test is appropriate
since the effect is only expected in one direction. A one-tailed Student’s t-test was
applied to assess the significance for the bleeding time prolongation in the mouse
tail bleeding experiment.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
The data supporting the findings of this study are available within the article and
Supplementary Information. All datasets generated during the current study are available
from the corresponding author on reasonable request. Source data are provided with
this paper.
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